Would a low or intermediate OncoType RS affect your choice of adjuvant endocrine therapy for a premenopausal woman with high clinical risk HR+ early stage disease?
Would you offer AI + OFS or tamoxifen to a woman with a grade 3 T2N0 tumor and OncoType of 15?